AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01510236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help program
Description: The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
Study NCT01718600 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological testing
Study NCT03158805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIRAGLUTIDE
Description: 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
Study NCT03158805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study NCT05427305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB008
Description: 15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
Study NCT05427305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
Study NCT01359150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
Study NCT01359150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
Study NCT02507466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Variable conditions of stepping practice
Study NCT02507466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Variable conditions of stepping practice
Study NCT03656042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (75mcg/0.3ml)
Description: Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment
Study NCT03486769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMC stimulation
Description: stimulating premotor cortex with anodal transcranial direct current stimulation
Study NCT03486769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aIPS stimulation
Description: stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
Study NCT03486769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hand motor task
Description: hand motor task for 30 minutes during transcranial direct current stimulation
Study NCT03663972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: articulation therapy
Description: children receive instruction in producing new sounds at the isolation, syllable and word level.
Study NCT03663972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: phonologic treatment
Description: children receive instruction in producing new sounds at the word level
Study NCT02557867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
Study NCT05040165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iceform liner and sleeve
Description: Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
Study NCT04207593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2>90% or pO2 >60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
Study NCT04207593 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxygen
Description: Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2>90% or pO2 >60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
Study NCT03595982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procardia XL 30Mg
Description: Procardia XL 30 mg XL Q 12h
Study NCT03595982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procardia XL 60Mg
Description: Procardia XL 60 mg Q 24h
Study NCT02425995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic intercondylar and posteromedial portal
Description: Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
Study NCT00578890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical/surgical treatment versus medical treatment
Description: A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
Study NCT00203996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWS supp
Description: SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
Study NCT02554487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)
Description: Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI > 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI \< 5) following stroke serve as a control group
Study NCT02848651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
Study NCT02551276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Study NCT02551276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02551276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Study NCT02551276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Study NCT01353326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cormet
Description: Cementless hip resurfacing system
Study NCT01353326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conserve
Description: Cemented hip resurfacing system
Study NCT06350825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive prostatectomy or brachytherapy
Description: local treatment+SOC for metastatic prostate cancer
Study NCT06350825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT+second-generation antiandrogens ± chemotherapy
Description: SOC(Triplet or doublet therapy) for mHSPC
Study NCT03122899 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SIJ fusion with iFuse-3D
Description: Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
Study NCT02412033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 µg misoprostol vaginally 3 hours before IUD insertion.
Study NCT02412033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive placebo
Study NCT01574040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of stair climbing
Description: Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories.
Study NCT01574040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a low-salt soup alternative for the 'soup of the day'
Description: Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure.
Study NCT01574040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a low-fat alternative for the butter croissants
Description: Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids.
Study NCT01574040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations
Description: Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
Study NCT01402791 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
Study NCT01700205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Type of Formula
Description: infant formula
Study NCT01700205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Formula
Description: infant formula
Study NCT01260896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride
Description: 150 mg Extended-Release Capsule
Study NCT01260896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® XR
Description: 150 mg Extended-Release Capsule
Study NCT04160936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine Injectable Product
Description: Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
Study NCT02188836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation
Description: Electromagnetic stimulation with a new device produced by the investigators for this study.
Study NCT02188836 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
Study NCT02394106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
Study NCT02394106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 1000 ml, administered once
Study NCT01401231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation psychotherapy
Description: Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
Study NCT01401231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Continued usual care (could include referral for medication or psychotherapy)
Study NCT02884245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens
Description: The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
Study NCT02575924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential medium
Description: administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
Study NCT02575924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-step medium
Description: administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
Study NCT00491894 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Glycopyrrolate Liquid
Description: Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
Study NCT03471585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
Study NCT03471585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
Study NCT01212744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG
Description: 0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
Study NCT01262339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTX-A
Description: 100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
Study NCT02477813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
Study NCT02438007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galeterone
Description: 2550 mg galeterone tablets once daily PO
Study NCT01974206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP0113
Description: intramuscular injection
Study NCT02438007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg enzalutamide capsules once daily PO
Study NCT03568409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABO-GLYC
Description: 3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
Study NCT03568409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ABO-GLYC Placebo
Description: 3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
Study NCT04162457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stevia
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
Study NCT04162457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
Study NCT04162457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
Study NCT04162457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
Study NCT01968967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615; RN316)
Description: 150 mg every 2 weeks, subcutaneous injection, 12 months
Study NCT01968967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection every 2 weeks for 12 months
Study NCT02098837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Dolutegravir 50mg once daily
Study NCT00571649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
Study NCT00571649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
Study NCT00571649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban placebo
Description: Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
Study NCT00571649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin placebo
Description: Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
Study NCT01974206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection
Study NCT03441035 — intervention group
Intervention type: OTHER
Intervention: General anesthesia and surgery (liver transplantation)
Description: The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
Study NCT01894048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qvar® (beclometasone dipropionate HFA)
Description: Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
Study NCT02224443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
Study NCT02224443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
Study NCT02224443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group C , Normal saline infusion will be given with the same infusion volume as group A and B
Study NCT02224443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate
Description: Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
Study NCT02224443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate
Description: Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
Study NCT02224443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane
Description: Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
Study NCT02224443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane
Description: Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
Study NCT03500016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: See under arm description.
Study NCT01373255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal iliac catheterization
Description: Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
Study NCT01210963 — intervention group
Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation